Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases

Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases

US Patent 11427590 · Granted Aug 30, 2022

Estimated economic value: $41,858,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer ima2025
Use of itaconate and its derivatives/analogues to induce hair growth2025
Prodrugs of itaconate and methyl itaconate2025
Glutamine antagonists and uses thereof2025
Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors2025
Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors2025
Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors2025
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor2024
Prodrugs of glutamine analogs2024
Prodrugs of hydroxamate-based GCPII inhibitors2024
2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a sm2023
2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a sm2023